BigHat Biosciences, a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform, has entered a collaboration with Janssen Biotech Inc., a Johnson & Johnson company.
 
The goal of this strategic collaboration is to combine the drug discovery, clinical development and data science expertise from Johnson & Johnson with BigHat’s Milliner platform, a suite of machine learning technologies integrated with a high-speed wet lab, to guide the design and selection of high-quality antibodies for multiple Neuroscience therapeutic targets. The agreement was facilitated by Johnson & Johnson Innovation.
 
BigHat’s antibody design platform, Milliner, integrates a synthetic biology-based high-speed wet lab with machine learning technologies into a full-stack antibody discovery and engineering platform, to engineer antibodies with more complex functions and better biophysical properties. According to BigHat, this approach reduces the difficulty of designing antibodies and other therapeutic proteins to tackle conditions ranging from chronic illness to life-threatening disease, while also speeding up candidate discovery and validation.
 
“We’re delighted to be collaborating with Johnson & Johnson to utilize BigHat’s Milliner platform to accelerate protein design,” stated Mark DePristo, CEO and Co-founder of BigHat. “We look forward to fueling our shared goal of creating breakthrough therapies faster in difficult-to-treat diseases.”